EMMPRIN Expression is Required for Response to Bevacizumab Therapy in HNSCC Xenografts

Por Newman, J. Robert, Helman, Emily E., Safavy, Seena, Zhang, Wenyue, Rosenthal, Eben L.
Publicado em 2008

FLUORESCENT LABELED ANTI-EGFR ANTIBODY FOR IDENTIFICATION OF REGIONAL AND DISTANT METASTASIS IN A PRECLINICAL XENOGRAFT MODEL

Por Gleysteen, John P., Newman, J. Robert, Chhieng, David, Frost, Andra, Zinn, Kurt R., Rosenthal, Eben L.
Publicado no Head Neck (2008)

Modulation of Tumor Cell Growth In Vivo by Extracellular Matrix Metalloprotease Inducer

Por Newman, J. Robert, Bohannon, Isaac A., Zhang, Wenyue, Skipper, Joni B., Grizzle, William E., Rosenthal, Eben L.
Publicado em 2008

Optical imaging predicts tumor response to anti-EGFR therapy

Por Helman, Emily E, Newman, J Robert, Dean, Nichole R, Zhang, Wenyue, Zinn, Kurt R, Rosenthal, Eben L
Publicado em 2010

Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147

Por Newman, J. Robert, Gleysteen, John P., Barañano, Christopher F., Bremser, Jennifer R., Zhang, Wenyue, Zinn, Kurt R., Rosenthal, Eben L.
Publicado em 2008

Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer

Por Dean, Nichole R., Newman, J. Robert, Helman, Emily E., Zhang, Wenyue, Safavy, Seena, Weeks, D.M., Cunningham, Mark, Snyder, Linda A., Tang, Yi, Yan, Li, McNally, Lacey R., Buchsbaum, Donald J., Rosenthal, Eben L.
Publicado em 2009